Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes[ J]. Postgrad Med, 2017, 129(7): 686-697. 19. Pratley RE, Cersosimo E. Use of canagliflozin in combination with and compared to incretin-based therapies in type 2...
CONCLUSION: The combination of a GLP-1 agonist and an SGLT2-inhibitor has additive effects on lowering HbA1c and systolic blood pressure, body weight and cardiac risk and has the potential to synergistically reduce cardiovascular events and decelerate renal decompensation. A large prospective study ...
SGLT2 inhibitorGLP‐1 analoguestype 2 diabetesweight lossThis study aimed to observe the effect of the novel combination of dual add-on therapy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on glycaemic control and weight in...
To assess the real-world efficacy and safety of canagliflozin therapy added to type 2 diabetes mellitus (T2DM) patients who have received a minimum 1 year of glucagon-like peptide-1 (GLP-1) agonist therapy.This pre-post observational study assessed the efficacy and safety of canagliflozin in a...
声音简介2型糖尿病中,最新循证证据提示哪些降糖药有降低心血管疾病风险?NEJM最新综述 豪斯医生666 SGLT2i与GLP1 agonist的降低心血管并发症循证 2021-052 回复@豪斯医生666 表情0/300发表评论 下载手机APP 7天免费畅听10万本会员专辑 当前评论用户 豪斯医生666 35310270 简介:内分泌医学博士 TA的其他评论 磺脲类...
Therefore, patients may be initiated on the lowest SGLT2 inhibitor dose available: canagliflozin 100 mg daily, dapagliflozin 10 mg daily, empagliflozin 10 mg daily, or ertugliflozin 5 mg daily. Combination With GLP-1 Receptor Agonists Although SGLT2 inhibitors offer a clear benefit in slowing ...
ASCVD = atherosclerotic cardiovascular disease; GLP1RA = glucagon-like peptide 1 receptor agonist; SGLT2i = sodium glucose cotransporter 2 inhibitor; TZD = thiazolidinedione. Download: Download high-res image (363KB) Download: Download full-size image Figure 2. Selecting Pharmacologic Therapy for ...
[1]. Subsequently, various cardiovascular and renal benefits have been demonstrated for empagliflozin and other agents in the sodium–glucose transporter-2 inhibitor (SGLT2i) [2,3,4,5,6,7,8,9,10,11,12,13] and glucagon-like peptide-1 receptor agonist (GLP-1 RA) [10,14,15,16,17,18,...
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor Diabetes Obes Metab, 19 (10) (2017), pp. 1353-1362, 10.1111/dom.12982 View in ScopusGoogle Scholar [53] I.C. Lega, S.E. Bronskill, M.A. Campitelli, J. Guan, N.M. Stall, K. Lam, et al. Sodium glucose cotransp...
Risk of serious adverse events between patients who were on metformin-SGIT2I and metformin-sulphonylureas combination therapies. RR risk ratio; CI confidence interval; df degrees of freedom; Met metformin; SGLT2I sodium-glucose co-transporter 2 inhibitor; SU sulfonylurea. Full size image Five tri...